Nusinersen Shows Long-Term SMA Success, Positive Data for an Investigational DMD Therapy, Zogenix to Resubmit Fenfluramine NDA
Neurology News Network for the week ending July 6, 2019.
This week, Neurology News Network covered a new analysis of NURTURE study data on nusinersen (Spinraza) in presymptomatic patients with spinal muscular atrophy (SMA), successful phase 1b findings for Pfizer's PF-06939926, an investigational gene therapy designed to treat Duchenne muscular dystrophy (DMD), and Zogenix's announcement that it intends to resubmit an NDA for fenfluramine (Finlepta) for Dravet syndrome following the receipt of the final minutes from the FDA following a Type A meeting. (transcript below).
Matt:
Welcome to Neurology News Network. I’m Matt Hoffman. Let’s get into the news from this week.
Results from additional analysis of the
Presented at the Cure SMA Annual SMA Conference and the 5th Congress of the European Academy of Neurology, the findings ultimately showed that 100% of the 25 infants treated with nusinersen were able to sit without support while 88% were able to walk independently. Notably, these are milestones which are not documented in the natural history of SMA.
Recently, Pfizer presented data from a
Zogenix announced that it has received the final minutes from the
The meeting followed a refusal to file letter which the FDA sent to Zogenix regarding fenfluramine (also known as ZX008) in which 2 issues were identified—the lack of non-clinical data on the chronic administration of the treatment and an incorrect dataset included in the application. Zogenix president and CEO Stephen J. Farr, PhD, expressed his satisfaction with the meeting to NeurologyLive®.
For more direct access to expert insight, head to neurologylive.com. This has been Neurology News Network. Thanks for watching.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.